SCHEMBL4374186

SCHEMBL4374186

CC(=O)Oc1ccc(C=CC(=O)C=Cc2ccc(OC(C)=O)cc2)cc1.CC(=O)Oc1ccc(C=CC(=O)C=Cc2ccc(OC(C)=O)cc2)cc1.CC(=O)Oc1ccc(C=CC(=O)C=Cc2ccc(OC(C)=O)cc2)cc1.CC(=O)Oc1ccc(C=CC(=O)C=Cc2ccc(OC(C)=O)cc2)cc1.[Pd].[Pd]

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 3/20 0.65
LMNA P02545 3/20 0.64
KMT2A Q03164 2/20 0.64
MAPT P10636 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
KDM4E B2RXH2 1/20 0.64
MEN1 O00255 1/20 0.64
TTR P02766 1/20 0.64
TP53 P04637 1/20 0.64
CYP3A4 P08684 1/20 0.64
JUN P05412 1/20 0.55
NFKB1 P19838 1/20 0.55
TUBB4A P04350 1/20 0.54
TUBB P07437 1/20 0.54
TUBA3C P0DPH7 1/20 0.54
TUBA1B P68363 1/20 0.54
TUBA4A P68366 1/20 0.54
TUBB4B P68371 1/20 0.54
TUBB3 Q13509 1/20 0.54
TUBB2A Q13885 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4368151 1.00 F3 (0.65) F3LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL4373949 1.00 F3 (0.65) F3LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL4370893 1.00 F3 (0.65) F3LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL4369837 0.98 F3 (0.67) F3LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL5598768 0.98 F3 (0.67) F3LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL609972 0.86 GSK3B (0.71) F3LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL609973 0.86 GSK3B (0.71) F3LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL2451780 0.86 MAPT (0.81) F3LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL10941162 0.86 MAPT (0.81) F3LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL11354408 0.86 MAPT (0.81) F3LMNAKMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436197-B2 Palladium complexes and polymerization and coupling processes thereof WEST CHESTER UNIVERSITY OF PENNSYLVANIA OF THE STATE SYSTEM OF HIGHER EDUCATION (US) 2013-05-07 US claimed
US-20090111962-A1 Palladium Complexes and Polymerization and Coupling Processes Thereof WEST CHESTER UNIVERSITY OF PENNSYLVANIA OF THE STATE SYSTEM OF HIGHER EDUCATION 2009-04-30 US claimed
WO-2016029216-A2 METHOD FOR PRODUCING AMIDINE DERIVATIVES BIOCRYST PHARMACEUTICALS, INC. (US) 2016-02-25 WO disclosed
US-8436197-B2 Palladium complexes and polymerization and coupling processes thereof WEST CHESTER UNIVERSITY OF PENNSYLVANIA OF THE STATE SYSTEM OF HIGHER EDUCATION (US) 2013-05-07 US disclosed
US-20090111962-A1 Palladium Complexes and Polymerization and Coupling Processes Thereof WEST CHESTER UNIVERSITY OF PENNSYLVANIA OF THE STATE SYSTEM OF HIGHER EDUCATION 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111962-A1 Palladium Complexes and Polymerization and Coupling Processes Thereof DDT, PDCD2L, PDCD1LG2 F3 1590/4885LMNA 4360/4885KMT2A 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.